Momenta Pharmaceuticals, Inc. (MNTA)

[min]

It seems to me the market is rational. The market is going to price MNTA based on the Net Present Value of future cash flows. Cash and receivables at the end of Q1 should be about $5.00/share. Add to that the perceived NPV of cash flows for generic Lovenox and other programs, apply a market multiple to get a rough value. Right now the market isn't putting great value on those future cash flows. With time and no TEVA generc Lovenox will build cash and future confidence If and when MNTA starts hitting some of Dew's milestones the perceived value of future cash flows will improved so will the stock price.